Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s ODAC Concerned About Off-Label, Long-Term Promacta Use

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline’s ITP treatment gets panel review May 30 onsite at ASCO.

You may also be interested in...



ODAC Unanimously Recommends GSK’s Promacta For ITP

FDA, committee members struggle to find ways to discourage long-term use of the drug for the chronic condition.

ODAC Unanimously Recommends GSK’s Promacta For ITP

FDA, committee members struggle to find ways to discourage long-term use of the drug for the chronic condition.

Amgen’s Platelet Booster Faces FDA Panel

Risk management plan is likely focus of March 12 ODAC meeting.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel